CFN Media

— Marks the first novel psilocybin analog to enter clinical development — — Patient recruitment to commence immediately — — Pharmacokinetic and safety data readout expected in Q4 2022 —     TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company...

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th   SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for...

The Company’s clinical-grade GMP MDMA product is now known as “Laneo”   VANCOUVER, June 24, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) has registered a trademark for its clinical-grade MDMA product, which shall be marketed as Laneo MDMA. PharmAla is currently the...